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Abstract
Diabetic neuropathy is a major complication of diabetes that results in the progressive
deterioration of the sensory nervous system. Mitochondrial dysfunction has been proposed to play
an important role in the pathogenesis of the neurodegeneration observed in diabetic neuropathy.
Our recent work has shown that mitochondrial dysfunction occurs in dorsal root ganglia (DRG)
sensory neurons in streptozotocin (STZ) induced diabetic rodents. In neurons, the nutrient excess
associated with prolonged diabetes may trigger a switching off of AMP kinase (AMPK) and/or
silent information regulator T1 (SIRT1) signaling leading to impaired peroxisome proliferator-
activated receptor γ coactivator-1α (PGC-1α expression/activity and diminished mitochondrial
activity. This review briefly summarizes the alterations of mitochondrial function and proteome in
sensory neurons of STZ-diabetic rodents. We also discuss the possible involvement of AMPK/
SIRT/PGC-1α pathway in other diabetic models and different tissues affected by diabetes.
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1. Introduction
Diabetes may lead to a number of complications that affect various tissues: heart and
skeletal muscle, retina, secretory glands, kidneys, and peripheral nerves. Chronic metabolic
stress induced by hyperglycemia resulting from either low insulin production in type 1
diabetes or decreased peripheral sensitivity to insulin in type 2 diabetes affects cellular
homeostasis in virtually all cell types. At the same time the cellular pathophysiology of
diabetes-induced impairments remain controversial. Diabetic neuropathy most often
develops in the midst of other complications observed in diabetes. The putative pathogenesis
of diabetic neuropathy includes increased polyol pathway activity leading to the
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accumulation of sorbitol and fructose (Oates, 2002, 2008), advanced glycation-end products
produced by non-enzymatic glycation of proteins (Duran-Jimenez et al., 2009; Thornalley,
2002), inappropriate activation of protein kinase C (Eichberg, 2002) and reduced
neurotrophic support – maintenance of normal phenotype of neurons is impaired due to
diabetes-induced loss of neurotrophic support by insulin, insulin-like growth factors (IGF-I,
IGF-II), nerve growth factor (NGF) and neurotrophin-3 (NT-3) (Calcutt et al., 2008).
Mitochondrial dysfunction occurs in a range of diabetic complications and given their
central role in controlling the bioenergetic status of the cell, may be considered a prime
trigger of nerve degeneration (Sivitz and Yorek, 2010). Our recent work has shown that
mitochondrial dysfunction occurs in dorsal root ganglia (DRG) sensory neurons in STZ
(streptozotocin)-diabetic mice and rats and is characterized by impaired electron transport
complex activities, reduced rates of oxidative phosphorylation and aberrant physiology in
axons (Akude et al., 2011; Chowdhury et al., 2010). Studies in muscle, liver and cardiac
tissues have shown that the AMP kinase (AMPK), silent information regulator T1 (SIRT1)
and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) signaling axis
senses the metabolic demands of cells and regulates mitochondrial function accordingly –
e.g. under nutrient starvation the pathway is activated to enhance ATP production (Feige and
Auwerx, 2007; Puigserver et al., 1998). SIRT1 and 3 are deacetylases that alter the functions
of an array of proteins including enzymes and histones and thus have far-reaching effects on
global gene expression. PGC-1α is a primary target of AMPK and SIRT1 that controls the
expression of a family of proteins required for mitochondrial function, biogenesis and
regeneration. Our general hypothesis is that in neurons, prolonged diabetes results in
nutrient excess and polyol pathway-mediated diminishment of the NAD+/NADH ratio. This
results in a switching off of AMPK and/or SIRT isoforms leading to impaired PGC-1α
expression/activity and a subsequent decrease in mitochondrial respiratory enzyme chain
activities.
2. Clinical impact and socio-economic burden of diabetes and diabetic
neuropathy
Diabetes causes about 5% of all deaths globally each year. It has received an increased
attention in recent decades due to its high prevalence and enormous economic burden on our
society. According to the Canadian Diabetic Association, an estimated 285 million people
world-wide have diabetes. With a further 7 million people developing diabetes each year,
this number is expected to hit 438 million by 2030
(http://www.diabetes.ca/diabetes-and-you/what/prevalence/). Data from 1997, published in
National Diabetes Fact Sheet, revealed that in the USA, 23.6 million children and adults had
diabetes and that another 57 million were in a pre-diabetic condition. Of those, about 90–
95% have non-insulin-dependent diabetes mellitus (Type 2 diabetes) and 5–10% have
insulin-dependent diabetes mellitus (Type 1 diabetes). In the USA, approximately $116
billion was spent in 2007 to cover direct health service costs for treatment of diabetic
complications that include retinopathy, nephropathy, heart disease, and neuropathy. The
indirect costs were $58 billion due to disability, work loss, and premature mortality. About
60% to 70% people with diabetes have mild to severe forms of nervous system damage. The
incidence of sensory and autonomic neuropathies in diabetic patients leads to incapacitating
pain, digestive abnormalities, erectile dysfunction, heart arrhythmia, sensory loss, foot
ulceration (up to 2 million Americans have this complaint), infection, gangrene and poor
wound healing. In the USA in 1998, approximately $15 billion of heath service expenditure
was associated with the neurological complications (sensory and autonomic neuropathy and
blindness). The end result is often lower extremity amputation which accounts for
approximately 80,000 cases each year in the USA. There is no effective therapy, only
palliative treatment is available at the present time. These alarming figures are estimated to
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rise by approximately 5-fold over the next 10 years due to the epidemic in obesity and the
associated increase in incidence and earlier time of onset of Type 2 diabetes ( from
American Diabetes Association web site:
http://www.diabetes.org/diabetes-basics/diabetes-statistics/).
3. Neurodegenerative features of diabetic sensory neuropathy
Diabetic neuropathy, the most common form of peripheral neuropathies, occurs with similar
functional, morphological, and metabolic changes documented in both human and animal
models of Type 1 and 2 diabetes. The features of this disease are associated with a reduction
of motor and sensory nerve conduction velocity and a wide range of structural changes in
peripheral nerves that includes endoneurial microangiopathy, abnormal Schwann cell
pathology, axonal degeneration, paranodal demyelination and loss of myelinated and
unmyelinated fibers - the latter due to a dying-back of distal axons that presents clinically as
reduced epidermal nerve fibre density (Estrella et al., 2008; Malik et al., 2005; Mizisin et al.,
2007; Mizisin et al., 2002; Sima, 2004; Yagihashi, 1997). The neurodegeneration is most
profound in the longest axons of neurons, and defective axon regeneration impedes tissue re-
innervation (Polydefkis et al., 2004). Apoptosis-dependent loss of sensory or sympathetic
neuron perikarya has not been found in diabetic humans or animals (Kamiya et al., 2006;
Kamiya et al., 2005; Schmidt et al., 1997a; Schmidt et al., 1997b; Sidenius and Jakobsen,
1980), although loss of small unmyelinated neurons does occur in long-term mouse models
of diabetes (Kennedy and Zochodne, 2005). The distal dying-back and formation of axonal
dystrophy (with swellings) of axons are critical pathological features (Kennedy et al., 1996;
Polydefkis et al., 2004; Schmidt et al., 1997b) and mimic axonal pruning and degeneration
observed in the CNS and PNS in other pathological states (Nja and Purves, 1978).
4. Mitochondria and diabetic neuropathy
Mitochondrial dysfunction has been implicated in the pathophysiology of diabetic
complications. The muscle, heart, kidney, and nerves all demonstrate abnormalities of
mitochondrial structure and function in both clinical and animal models of diabetes.
Mutation or loss of proteins associated with mitochondrial function can lead to neuropathy
that mimics that seen in diabetes, for example, loss of function of mitofusin-2 or bcl-w
results in a length-dependent sensory fiber degeneration (Baloh et al., 2007; Courchesne et
al., 2011; Pazyra-Murphy et al., 2009). Studies on mitochondrial physiology in diabetic
neuropathy lag behind those in other diabetic complications, such as in muscle,
cardiomyopathy and nephropathy. Table 1 summarizes findings in an array of animal
models, and in humans, in Type 1 and 2 diabetes with respect to analysis of functioning of
the mitochondrial respiratory chain. In general, mitochondrial-based electron transport
functions are diminished.
4. 1. Altered mitochondrial oxidative phosphorylation and proteome in diabetic sensory
neuropathy
Our recent published results on mitochondrial function in DRG of STZ-diabetic rats are in
general agreement with those findings described in muscle, heart and kidney (Akude et al.,
2011; Chowdhury et al., 2010; Zherebitskaya et al., 2009). Rates of coupled respiration with
pyruvate + malate (P + M; full respiratory chain) and with ascorbate + TMPD (Asc +
TMPD; Complex IV) in lumbar DRG were unchanged up to 12 weeks of diabetes
(Chowdhury et al., 2010). By 22 weeks of diabetes, respiration with P + M was significantly
decreased by 31–44% and with Asc + TMPD by 29–39% in STZ-diabetic rats compared to
control. Attenuated mitochondrial respiratory activity of STZ-diabetic rats was significantly
improved by insulin treatment (Fig. 1 taken from (Chowdhury et al., 2010)). Enzymatic
activities of mitochondrial complexes I and IV and the Krebs cycle enzyme, citrate synthase,
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were decreased in mitochondria from DRG of 22 week STZ-diabetic rats compared to
control (Fig. 2 taken from (Chowdhury et al., 2010)). The diabetes-induced factors causing
reduced rates of respiratory complex activities remain poorly understood, however,
investigators have begun to use proteomic and gene array techniques to identify alterations
in gene expression that presumably underpin such changes in mitochondrial physiology (for
example, see (Bugger et al., 2009)). The stable isotope labeling with amino acids in cell
culture (SILAC)-based quantitative proteomics analysis of mitochondrial protein expression
in the mitochondria from 22 week STZ-diabetic rats by our group revealed that diabetes
altered the levels of an array of proteins (mitochondrial complexes - Complex I-V,
tricarboxylic acid (TCA) cycle, oxidative stress, fatty acid utilization) associated with the
mitochondrial function (Table 2 taken from (Akude et al., 2011)). Reduced expression of
oxidative phosphorylation genes have been found in Type 2 diabetes (Patti et al., 2003), and
decreased expression of the transcriptional regulator, nuclear respiratory factor 1 (NRF-1)
and the translational co-activator, PGC-1α were observed in pre-diabetic and diabetic
muscle (Mootha et al., 2003). Our results showing reduced expression of NADH
dehydrogenase Fe-S protein 3 (NDUFS3) and subunit IV of cytochrome c oxidase (COX
IV) in lumbar DRG of STZ-induced diabetic mice (Fig. 3) and rats (Chowdhury et al., 2010)
are consistent with these findings and support the premise that reduced activity of the
mitochondrial respiratory chain could result from a proteome alteration leading to reduced
expression/activity of a range of mitochondrial components. We have proposed that this
broad spectrum of protein expression changes underpin the altered activity and physiology
of the mitochondria in neurons in diabetes resulting in impaired bioenergetics in axons and
subsequent degeneration.
4.3. Oxidative stress in diabetic neuropathy
Oxidative stress has been implicated in the pathological process inducing nerve damage in
diabetes (Obrosova, 2002; Vincent et al., 2004). Oxidative stress, possibly triggered by
vascular abnormalities and associated microangiopathy in the nerve (Cameron et al., 2001;
Malik et al., 2005), is a key pathological process inducing nerve damage in diabetes in
humans and experimental models (Obrosova, 2002; Vincent et al., 2004). Diabetes-induced
oxidative stress in sensory neurons and peripheral nerve is demonstrated by increased
production of reactive oxygen species (ROS) (Coppey et al., 2003; Nishikawa et al., 2000b;
Oltman et al., 2009; Russell et al., 2002), lipid peroxidation (Obrosova et al., 2002), protein
nitrosylation (Obrosova et al., 2005a; Obrosova et al., 2005b), and reduced levels of reduced
glutathione (Ho et al., 2006; Obrosova et al., 2002) and ascorbate (Obrosova et al., 2002).
The neurodegenerative outcome is energy failure in the nerve, observed as a decrease in
high energy intermediates (e.g. phosphocreatine) (Obrosova, 2002; Vincent et al., 2004),
impaired axonal transport of proteins (Fernyhough and Schmidt, 2002) and sub-optimal ion
pumping (Hall et al., 1995; Huang et al., 2002; Kruglikov et al., 2004). However, treatments
with anti-oxidants such as α-lipoic acid, γ-linolenic acid and aldose reductase inhibitors
have shown to prevent many indices of neuropathy in STZ-diabetic rats (Obrosova, 2002;
Vincent et al., 2004; Yorek et al., 2004).
Elevated production of reactive oxygen species (ROS) and mitochondrial hyperpolarization
are exhibited by cultured endothelial cells after a short period of exposure to high [glucose]
that may drive excessive electron donation to the electron transport chain in mitochondria
(Nishikawa et al., 2000b). Brownlee et al. have proposed that this mitochondrial-dependent
process is a central mediator of oxidative stress in complications of diabetes (Nishikawa et
al., 2000a; Nishikawa et al., 2000b). Studies in cultured embryonic sensory neurons have
shown that high [glucose] induces toxicity through an apoptotic route involving a
mitochondrial-dependent pathway (Vincent et al., 2004). But studies on adult sensory
neurons from normal and STZ-diabetic rats indicate that adult neurons have different
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responses to high [glucose] compared with endothelial cells and embryonic neurons. Our
work and studies by Wiley et al. have shown that in adult sensory neurons from STZ-
diabetic rats, the mitochondrial inner membrane potential is depolarized, not hyperpolarized
as observed in endothelial cells exposed to high [glucose] (Huang et al., 2003; Huang et al.,
2005; Srinivasan et al., 2000). In our recent study, impaired mitochondrial respiratory chain
activity was not accompanied by increased ROS production in neuronal perikarya from
STZ-diabetic rats (Chowdhury et al., 2010). However, we have recently found that ROS
levels and protein adducts of 4-hydroxy-2-nonenal are elevated in the presence of high
glucose concentration in axons of adult sensory neurons isolated from 3- to 5-month STZ-
diabetic rats, with the perikarya being unaffected (Zherebitskaya et al., 2009). These results
suggest that mitochondrial function may differ between axons and perikarya or that
oxidative stress in axons and other cells of the nerve trunk may derive from alternative
sources. One of our studies also provides preliminary evidence that the sources of ROS in
axons of diabetic neurons may, in part, derive from the polyol pathway. This pathway has
been proposed as a source of ROS through a putative sorbitol accumulation-dependent
NADPH oxidase route in previous studies (Ido et al., 2010; Oates, 2008). In agreement with
this evidence, the specific sorbitol dehydrogenase inhibitor, SDI-158, blocked high
[glucose]-dependent ROS production in the axons of diabetic neurons (Akude et al., 2011).
5. AMPK/SIRT/PGC-1α pathway in neurons
AMPK is a major metabolic sensor and master regulator of metabolic homeostasis (Hardie,
2007). SIRT1 plays an important role in metabolic function and longevity in mammals. Both
AMPK and SIRT1 act in concert with the master regulator of mitochondrial biogenesis,
PGC-1α to regulate energy homeostasis in response to environmental and nutritional stimuli
(Hardie, 2007; Reznick and Shulman, 2006). Studies on this signaling axis in neurons
remain remarkably limited. Resveratrol activates AMPK in cultured neurons (Dasgupta and
Milbrandt, 2007) and in animal models of Huntington and Alzheimer’s disease, PGC-1α
and SIRT1 are protective (Kim et al., 2007; St-Pierre et al., 2006). In Type 1 diabetic rats,
resveratrol improved indices of neuropathy (Kumar et al., 2007; Sharma et al., 2009).
5.1. PGC-1α and cell metabolism
PGC-1α is a potent coactivator of a plethora of transcription factors impacting on whole-
body energy expenditure, including myocyte enhancer factor-2, forkhead O-box (FOXO)
transcription factors and nuclear receptors (e.g. PPARs and estrogen-related receptors)
(Feige and Auwerx, 2007; Michael et al., 2001; Puigserver et al., 2003; Vega et al., 2000).
By way of these varied interactions, PGC-1α coordinately regulates gluconeogenesis,
glycolysis, lipogenesis, peroxisomal and mitochondrial fatty acid oxidation, and
mitochondrial respiration efficiency. PGC-1α is mainly expressed in tissues with high
energy oxidative capacity such as heart, skeletal muscle, liver, brown adipose tissue and
brain, and is robustly induced in conditions requiring energy, e.g. cold, fasting and exercise
(Puigserver et al., 1998). Over-expression of PGC-1α induces increased mitochondrial
number and function (Lin et al., 2002). Conversely, deletion of PGC-1α results in abnormal
glucose homeostasis and decreased mitochondrial function (Handschin et al., 2007).
Decreased PGC-1α levels have been reported in skeletal muscle from insulin-resistant and
Type 2 diabetic patients (Mootha et al., 2003; Patti et al., 2003; Richardson et al., 2005).
PGC-1α activity is regulated by both its expression level and by posttranslational
modifications involving acetylation and phosphorylation (Rodgers et al., 2008). Two
proteins, SIRT1 and AMPK, play major roles in metabolic regulation and have recently been
shown to impact on PGC-1α to transcriptionally regulate energy expenditure (Rodgers et al.,
2008).
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5.2. SIRT1 and the control of PGC-1α activity
SIRT1 is a cytoplasmic enzyme (SIRT3 is the mitochondrial form) that mediates NAD+-
dependent deacetylation of target substrates. SIRT1 acts as a sensor of NAD+ levels that
directly connects metabolic perturbations with transcriptional outputs; it was initially
characterized as a histone deacetylase (Bao and Sack, 2010). High NAD+/NADH ratios
activate SIRT1, which can directly interact with and regulate the activity of transcription
factors and co-regulators, including PGC-1α, PPAR-γ, p53 and the FOXO family of
transcription factors (Nemoto et al., 2005; Rodgers et al., 2005). Deacetylation of PGC-1α
increases its transcriptional activity and acetyltransferase enzymes have been demonstrated
to inhibit PGC-1α activity by increasing its acetylation (Canto and Auwerx, 2009). SIRT1-
mediated regulation of PGC-1α activity may play a major role in the metabolic adaptations
to energy metabolism in different tissues (Canto and Auwerx, 2010). Recent work shows
high glucose can down-regulate SIRT1 expression in endothelial cells (Balestrieri et al.,
2008) and the diabetic state lowers the NAD+/NADH ratio in retina and nerve (Ido et al.,
2010; Li et al., 2004; Oates, 2008; Obrosova et al., 2006).
5.3. AMPK and linking PGC-1α activity to energy status
AMPK is a multi-component Ser/Thr kinase activated by direct binding of AMP upon a rise
in the cellular AMP/ATP ratio (Hardie, 2008). Once activated, AMPK switches on catabolic
pathways to produce ATP while simultaneously shutting down energy-consuming anabolic
processes. To perform these actions, AMPK quickly regulates metabolic enzymes through
direct phosphorylation, but also has long-term effects at the transcriptional level to adapt
gene expression to energy demands. Mice expressing a dominant-negative form of AMPK
cannot increase mitochondrial biogenesis in response to energy deprivation in skeletal
muscle (Zong et al., 2002). In mice overexpressing an activated form of the AMPK-γ3
subunit, the expression of genes controlling lipid oxidation and mitochondrial activity are
induced (Garcia-Roves et al., 2008). There is a strong overlap in genes that are
transcriptionally regulated by AMPK and PGC-1α, suggesting that PGC-1α may be an
important mediator of AMPK-induced gene expression (Feige and Auwerx, 2007). AMPK
activation increases PGC-1α expression/phosphorylation and AMPK requires PGC-1α
activity to modulate the expression of several key players in mitochondrial and glucose
metabolism (Jager et al., 2007). There is also a positive feedback loop linking AMPK with
SIRT1. SIRT1 elevates AMPK activity through deacetylation of LKB1, the upstream kinase
which phosphorylates and activates AMPK (Lan et al., 2008), and AMPK enhances SIRT1
via elevation of NAD+ (Bao and Sack, 2010). Finally, high glucose concentration and/or
nutrient excess leads to down-regulation of AMPK activity in several cell types (da Silva
Xavier et al., 2003; Mountjoy et al., 2007; Mountjoy and Rutter, 2007).
5.4. Diabetes in mice down-regulates AMPK and PGC-1α
In DRG from STZ-diabetic Swiss Webster mice, the expression of phosphorylated (P-
AMPK), and PGC-1α was decreased significantly by 8 wks (Fig. 4). The lowered activation
status of the up-stream regulators of mitochondrial biogenesis, AMPK and PGC1-α
correlated with the down-regulation of an array of mitochondrial proteins confirmed by
Western blotting and proteomic analysis ((Akude et al., 2011) and Table 2). The most
significant changes were decreased levels of mitochondrial enzyme components involved in
oxidative phosphorylation (NDUFS3, COX IV), the Kreb’s cycle enzyme (citrate synthase)
and the oxidative stress scavenger (Mn-superoxide dismutase). In the cardiac system,
diminished mitochondrial respiratory function caused by diabetes has also been identified by
proteomics and gene array techniques (Bugger et al., 2008; Bugger et al., 2009). These
broad changes in gene expression could be triggered by altered activity of key upstream
regulators. In human skeletal muscle in Type 2 diabetes, the transcriptional regulator, NRF-1
and the transcriptional co-activator, PGC-1α were downregulated and corresponded with
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reduced expression of proteins that regulate cellular energy metabolism, including
mitochondrial biogenesis and oxidative phosphorylation (Mootha et al., 2003; Patti et al.,
2003). In addition, a recent report by Iwabu et al, clarified that adiponectin (anti-diabetic
adipokine) and adiponectin receptor 1 regulate PGC-1α and mitochondria through Ca2+ and
AMPK/SIRT1 (Iwabu et al., 2010). In fact, our preliminary data identified a significant
reduction in activity of SIRT3 in DRG of type 1 diabetic rodents (data not shown). Our
results in STZ-diabetic mice presented in Figs. 3 and 4 along with the decreased level of
SIRT3 support a causal link between AMPK/SIRT/PGC-1α pathway and mitochondrial
dysfunction in sensory neuropathy developed under diabetic conditions.
6. Possible mechanism of induction of diabetic sensory neuropathy
Sensory neurons do not exhibit insulin-dependent glucose uptake, thus hyperglycemia leads
to nutrient excess and so the AMPK/SIRT/PGC-1α pathway is deactivated. The scheme in
Fig. 5 shows that this results in a general down-regulation of mitochondrial oxidative
capacity and increased susceptibility to cell stress. This process is akin to the ‘Crabtree
effect’ since ATP resources are considered by the cell body to be adequate and so oxidative
phosphorylation can be deactivated and anaerobic metabolism, e.g. glycolysis, can suffice.
In highly polarized cells such as neurons this may create a unique metabolic problem in
specific cellular compartments (e.g. the high energy requiring distal axon). In addition,
elevated glucose flux through the polyol pathway leads to high rates of sorbitol oxidation
and diminishment in the NAD+/NADH ratio (in the cytoplasm and mitochondria). This will
effectively lower NAD+ levels and so reduce SIRT1/3 activity. In addition, the raised
NADH levels will enhance oxidative stress, in part, through elevated NADPH oxidase as
proposed by Williamson et al (Ido et al., 2010). Our recent paper provides pharmacological
evidence that sorbitol oxidation contributes to oxidative stress in axons of diabetic neurons
(see Figure 5 in (Akude et al., 2011)).
Another aspect of mitochondrial biology that may be relevant to diabetic neuropathy is the
possible involvement of autophagosomes. The presence of increased levels of
autophagosomes in DRG neurons of STZ-induced diabetic rats with the co-localization of
mitochondria in neuronal soma described by Towns et al. suggests that autophagy may be
indicative of, or may contribute to, the mitochondrial dysfunction in diabetic neuropathy
(Towns et al., 2008; Towns et al., 2005). Our hypothesis detailing a diabetes-dependent shift
towards an anaerobic source of ATP would support the need to remove unnecessary or
dysfunctional mitochondria – and this would be reflected by elevated autophagy of this
organelle. However, while the work from the Wiley group is interesting further confirmation
is needed and in particular ultrastructural identification of autophagosomes is required over
a time course of development of diabetic neuropathy. At this juncture numerous electron
microscope-based ultrastructural studies of DRG neuronal perikarya from human, STZ-
induced and BB diabetic rats have been performed over the years but have failed to identify
the classic double membrane structure of this organelle (Kamiya et al., 2006; Schmidt et al.,
1997b).
In conclusion, we hypothesize that high glucose-induced AMPK/SIRT/PGC-1α down-
regulation in neurons is a maladaptive process that explains the length dependent loss of
distal nerve endings. The constantly plastic axonal endings of fibers in the skin require
enormous amounts of ATP to be maintained and to permit collateral sprouting (Bernstein
and Bamburg, 2003). This in turn demands a sufficient supply of actively respiring
mitochondria. Hyperglycemia-induced loss of the AMPK/SIRT/PGC-1α pathway in
diabetic neurons may lead to a dearth of fully functioning mitochondria that ultimately
triggers distal axonal death, a hallmark of severe diabetic peripheral neuropathy.
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Mitochondrial dysfunction occurs in a range of diabetic complications and given its central
role in controlling the bioenergetic status of the cell must be considered a prime trigger of
degeneration. It remains unclear how such impaired mitochondrial function triggers cell
damage. Enhanced ROS production remains an unproven possibility. Failure to synthesize
adequate ATP for high energy requiring axonal functions such as excitation, axonal
transport and growth cone motility would seem more attractive options, particularly in
neurons. In diabetic neuropathy, studies have begun to outline the array of impairments in
mitochondrial physiology, although studies still lag behind those in nephropathy and
cardiomyopathy. Diabetes-induced changes in mitochondrial phenotype would seem key
factors leading to altered activity of the respiratory chain and Krebs cycle components.
Aberrant growth factor-dependent signaling, especially through the insulin pathway could be
involved (Ishii, 1995; Zochodne, 2008), however, hyperglycemia and associated raising of
intracellular glucose concentration maybe a central trigger of altered mitochondrial
proteome expression. In many cell types, high intracellular glucose causes inhibition of
oxidative phosphorylation and enhances anaerobic glucose metabolism through glycolysis,
known as the Crabtree effect (Ibsen, 1961). The glucose-dependent signal transduction
pathway that is proposed to become active in the diabetic state and that initiates altered cell
bioenergetics in neurons needs to be dissected and manipulated in vitro and in vivo. There is
a plausible role for the polyol pathway in such a paradigm, however, it must be remembered
that neurons do not express aldose reductase and so the activity of such a pathway in
neurons in diabetes remains unclear (Jiang et al., 2006).
The involvement of deacytylases, such as the sirtuins, along with AMPK and PGC-1α in the
mitochondrial dysfunction seen in sensory neuropathy could explain the broad array of
phenotypic changes that underlie the altered mitochondrial physiology observed. There is a
strong level of inter-dependence between the AMPK, SIRT and PGC1α components in
diabetic neuropathy. Therefore, a focus on the AMPK/SIRT/PGC-1α pathway in sensory
neurons will provide a novel approach to explaining its role on the pathogenesis of the distal
axonopathy seen in diabetes and its potential for pharmacologic targeting to help reverse
features of the sensory neuropathy. However, given the central nature of this pathway to
energy homeostasis in numerous tissues, a major challenge will likely be avoiding untoward
side effects that impair their function in non-target tissues.
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Figure 1. Effect of 12–22 wks of STZ diabetes on the electron transport chain activity of
mitochondria in freshly prepared lumbar DRG tissue homogenate
A Clarke type electrode (OROBOROS oxygraph 2K) was used to measure oxygen
consumption – a direct measure of rate of electron transport in mitochondria. Measurements
of oxygen consumption were performed with energetic substrates, pyruvate and malate. A.
Basal respiration, B. Pyruvate + Malate + ADP (coupled oxidative phosphorylation), and C.
the respiration rate with Asc + TMPD (Complex IV) were assessed age-matched control
(Ctrl), STZ diabetic rats (Db), and STZ diabetic rats with insulin implant (Db + Ins) at 12 (n
= 5 ), 16 (n = 7–11), and 22 (n = 5–6) wks of diabetes. Values are means ± SD, n = as
indicated. *P<0.05 vs Db + Ins; **P<0.001 vs Db (one-way ANOVA with Tukey’s posthoc
comparison). Copyright 2010 American Diabetes Association. From Diabetes, vol. 59, 2010;
1085. Reprinted with permission from the American Diabetes Association.
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Figure 2. Enzymatic activities of mitochondrial respiratory chain and citrate synthase activity
are decreased in isolated mitochondria from lumbar DRG of STZ-diabetic rats
Enzymatic activity of Complex I was assessed as (A) rotenone-sensitive portion of NADH-
cytochrome c reductase (NCCR) (n = 5), (B) cytochrome c oxidase (n = 6–7) and (C) citrate
synthase (n = 5) were measured as described in Research Design and Methods. Values are
means ± SD, n = as indicated. *P<0.05 vs Ctrl (unpaired Student’s t–test). Copyright 2010
American Diabetes Association. From Diabetes, vol. 59, 2010; 1087. Reprinted with
permission from the American Diabetes Association.
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Figure 3. Protein levels of mitochondrial respiratory chain components are reduced in DRG
from STZ-diabetic mice
Western blotting revealed diminished expression of some components of the mitochondrial
electron transport chain. NDUFS3 (component of Complex I) and COX IV (component of
Complex IV) were significantly decreased, whereas levels of ATP-synthase-β subunit and
ERK remained unaltered. Shown are representative blots (A–C) and charts in which
NDUFS3 (D), COX IV (E), and ATP-synthase β subunit signal (F) have been presented
relative to total ERK level. Values are means ± SEM, n = 6. *P<0.05 vs Ctrl (unpaired
Student’s t test).
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Figure 4. Expressions of P-AMPK and PGC-1α are down-regulated in STZ-diabetic mice
A down-regulation of mitochondrial proteins was associated with lowered activation status
of the up-stream regulators of mitochondrial biogenesis, AMPK and PGC-1α. The Western
blotting expressed reduced activation of phosphorylated AMPK (P-AMPK) coupled with
diminished level of PGC-1α whereas total AMPK (T-AMPK) and ERK remain unchanged.
Shown are representative blots (A–C) and charts in which P-AMPK (D), T-AMPK (E), and
PGC-1α signal (F) have been presented relative to total ERK level. Values are means ±
SEM, n = 6. *P<0.05 vs Ctrl (unpaired Student’s t test).
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Figure 5. Mitochondrial dysfunction in sensory neurons due to diabetes through the AMPK/
SIRT/PGC-1 α pathway
Nutrient excess or hyperglycemia combines to alter mitochondrial function. High
intracellular [glucose] in neurons may cause a general downregulation of mitochondrial
oxidative capacity, possibly through the involvement of AMPK/PGC-1α pathway. Under
nutrient depletion (starvation, exercise) or the influence of resveratrol or AICAR, the
pathway is activated. In addition, elevated glucose flux through the polyol pathway leads to
high rates of sorbitol oxidation and a decrease in the cytoplasmic and mitochondrial NAD+/
NADH ratio. This will effectively lower NAD+ levels and reduce SIRT1/3 activity. There is
also a positive feedback loop linking AMPK with SIRT1 wherein SIRT1 elevates AMPK
activity through deacetylation of LKB1 and AMPK enhances SIRT1 through elevation of
NAD+.
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TABLE 1
Summary of mitochondrial alterations in tissues affected by diabetes.
Diabetic model, tissue/culture Aberrant mitochondrial physiology References
Type 1 diabetes
STZ-rat, cerebral cortex ↓ Enzymatic activity (Complex I, II and IV)
↓ Protein level of Mn-SOD
↑ Cytochrome c release, caspase-3 Presence of mitochondrial
swelling
↓ Mitochondrial thiol content
(Kamboj and Sandhir,
2010)
STZ-mice, myocardium ↓ Respiration (Complex I, II, and IV)
↓ Enzymatic activity of Complexes I, III and V
↓ mitochondrial content (mt-DNA)
(Dabkowski et al., 2009;
Yang et al., 2009; Yu et al.,
2007)
STZ-rat, heart ↓ Respiration (glutamate + malate, succinate, FCCP)
↓Enzymatic activity of Complex I and II; ↑ UCP3, ↓ ANT1
(Herlein et al., 2009; Lashin
et al., 2006)
Chronic OVE26 diabetic mice, heart ↓ Respiratory rate at state 3 and 4, respiratory ratio (Shen et al., 2004)
Diabetic Akita mouse, heart ↓ Respiration (glutamate, pyruvate), ↓enzymatic activity of Complex
V, ↓mRNA level (oxidative phosphorylation, antioxidant defense), ↑
UCP3
(Bugger et al., 2008;
Bugger et al., 2009)
STZ-rat, kidney ↓ Enzymatic activity of Complex I, III, and IV ↑ membrane potential,
pyruvate content, Complex V activity
(de Cavanagh et al., 2008;
Munusamy et al., 2009)
Type 2 diabetes
Diabetic patients, skeletal muscle
biopsy
↓ Respiratory rate at state 3, uncoupled respiration, respiratory
control index
↓ Enzymatic activity of Complex I, V and CS
↓ Size of skeletal muscle mitochondria
(Abdul-Ghani et al., 2009;
Boushel et al., 2007; Kelley
et al., 2002; Mogensen et
al., 2007; Phielix et al.,
2008)
Diabetic patients, skeletal muscle
biopsy
↓Respiration with substrates for Complex I (pyruvate, malate,
glutamate) and for Complex II (succinate), no significant difference
when normalized to CS activity
(Rabol et al., 2009a, b;
Rabol et al., 2009c)
Diabetic Goto-Kakizaki rats, skeletal
muscle
↓ Enzymatic activity and protein expression of Complex I and II, mt-
DNA
(Shen et al., 2008)
Zucker diabetic fatty rats, skeletal
muscle
↓ Enzymatic activity of Complex IV and CS normal skeletal muscle
mitochondrial oxidative capacity, 31P magnetic resonance
spectroscopy
(De Feyter et al., 2008)
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TABLE 2
Effect of diabetes and insulin therapy on representative proteins annotated to mitochondria.
Symbol Protein description Relative to control
Relative to
Insulin treated




Ndufs3 NADH dehydrogenase (ubiquinone) Fe-S protein 3 0.64 0.84 131
Ndufv1 NADH dehydrogenase (Ubiquinone) flavoprotein 1 1.13 0.82 73
Ndufa10 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit
10
0.73 0.79 108
Ndufv2 NADH dehydrogenase [ubiquinone] flavoprotein 2 0.91 0.88 97
Ndufs2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2 0.48 0.54 113
Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit 0.78 0.91 117
Nd4 NADH dehydrogenase subunit 4 0.43 0.56 130
Ndufa9 Ndufa9 protein 0.87 1.19 137
Ndufs8 Ndufs8 protein 0.91 1.34 147
Complex II
Sdha Succinate dehydrogenase [ubiquinone] flavoprotein subunit 1.10 1.14 104
Sdhb Succinate dehydrogenase [ubiquinone] iron-sulfur subunit 1.11 1.15 104
Complex III
Uqcrc1 Cytochrome b-c1 complex subunit 1 0.87 1.26 145
Uqcrc2 Cytochrome b-c1 complex subunit 2 0.90 1.18 131
Uqcrfs1 Cytochrome b-c1 complex subunit Rieske 0.87 1.10 126
Complex IV
Cox4i1 Cytochrome c oxidase subunit 4 isoform 1 0.71 0.89 125
Cox5a Cytochrome c oxidase subunit 5A 0.83 1.28 154
COX2 cytochrome c oxidase subunit II 0.82 1.06 129
Complex V
Atp5c1 ATP synthase gamma chain 0.90 1.29 143
Atp5a1 ATP synthase subunit alpha 0.89 1.19 134
Atp5f1 ATP synthase subunit b 0.92 1.31 142
Atp5b ATP synthase subunit beta 0.90 1.10 122
Atp5jd ATP synthase subunit d 0.86 1.21 141
Atp5d ATP synthase subunit delta 0.69 0.92 133
Atp5i ATP synthase subunit e 0.75 0.81 108
Atp5o ATP synthase subunit O 0.88 1.13 128




Cs Citrate synthase 0.92 1.11 121
Aco2 Aconitate hydratase 0.98 1.11 113
Idh2 Isocitrate dehydrogenase [NADP] 0.96 1.25 130
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Symbol Protein description Relative to control
Relative to
Insulin treated
% of change of
insulin treated
vs. diabetic
Idh3a Isocitrate dehydrogenase [NAD] subunit alpha 0.89 1.03 116
Idh3B Isocitrate dehydrogenase [NAD] subunit beta 0.87 1.49 171
Fh1 Fumarate hydratase 1 0.55 1.19 216
Mdh2 Malate dehydrogenase 0.92 1.10 120
Ogdh 2-oxoglutarate (α-ketoglutarate) dehydrogenase E1 component 0.87 1.09 125
Oxidative stress related
Sod2 Superoxide dismutase [Mn] 0.73 1.08 148
Aldh2 Aldehyde dehydrogenase 0.98 1.19 121
Prdx3 Peroxiredoxin-3 0.87 1.26 146
Prdx5 Peroxiredoxin-5 0.74 0.86 116
Heat shock proteins
Hspe1 10 kDa heat shock protein 0.96 0.94 98
Hsp60 60 kDa heat shock protein 0.93 0.98 105
Hsp90aa1 HSP 90-alpha 0.79 1.32 167
Hsp90ab1 HSP 90-beta 0.83 1.37 165
Fatty acid utilization
Cpt1a Carnitine O-palmitoyltransferase 1, liver isoform 0.51 0.77 151
Acat1 Acetyl-CoA acetyltransferase 0.74 1.01 136
Acaa1a acetyl-Coenzyme A acyltransferase 1 0.81 1.3 160
Echs1 Enoyl-CoA hydratase 0.80 1.18 148
Hadh Hydroxyacyl-coenzyme A dehydrogenase 0.93 1.14 123
Hsd17b10 Hydroxysteroid (17-beta) dehydrogenase 10 0.71 1.14 161
Acadl Long-chain specific acyl-CoA dehydrogenase 1.00 0.99 99
Acadm Medium-chain specific acyl-CoA dehydrogenase 0.91 1.19 131
Acadvl Very long-chain specific acyl-CoA dehydrogenase 0.82 1.04 127
Hadha Trifunctional enzyme subunit alpha 0.89 1.10 124
Hadhb Trifunctional enzyme subunit beta 0.82 1.04 127
Other proteins
Cyb5b Cytochrome b5 type B 0.71 0.97 137
Ant1 ADP/ATP translocase 1 0.84 1.15 137
Ant2 ADP/ATP translocase 2 0.87 1.22 140
Ckmt Creatine kinase 1.52 0.80 53
Cycs Cytochrome c, somatic 0.56 0.90 161
Cyc1 cytochrome c-1 0.85 1.11 131
Glud1 Glutamate dehydrogenase 1 0.90 1.08 120
Gpd2 Glycerol-3-phosphate dehydrogenase 0.83 1.16 140
Hk1 Hexokinase-1 0.74 0.93 126
Ldha L-lactate dehydrogenase A chain 1.13 1.86 165













Roy Chowdhury et al. Page 23
Symbol Protein description Relative to control
Relative to
Insulin treated
% of change of
insulin treated
vs. diabetic
Fis1 Fis1 protein 0.59 0.97 164
Tomm70a Mitochondrial import receptor subunit TOM70 1.06 0.65 61
Table 2 represents a summary of our own mass spectrometry data of protein expression related to mitochondria and affected by diabetes and its
correction by insulin therapy. Changes in percent represent the effect of insulin treatment on the protein expression ratio measured from diabetic
rats. Copyright 2011 American Diabetes Association. From Diabetes, vol. 60, 2011; 291. Reprinted with permission from the American Diabetes
Association.
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